NIMS’ Acceleration Platform Technology Effective In Severe Experimental Hemorrhagic Shock
June 2nd, 2008 | by admin |Marvin A Sackner, M.D., Chief Executive Officer and Chairman, Board of Directors, Non-Invasive Monitoring Systems, Inc. [NIMS] (OTCBB:NIMU) announced that Dr. Jose A Adams, Dr. Uryash and their group at Mount Sinai Medical Center of Greater Miami presented two papers at the 9th Scientific Congress of the European Resuscitation Council held in Ghent, Belgium from May 21-24, 2008. Both studies involved applications of NIMS’ patented acceleration therapeutic platform technology. In humans, this non-invasive device is called Exer-Rest® and has the configuration of a single or twin bed fitted with a memory foam mattress. Electrical actuation of this device produces whole body periodic acceleration (WBPA) through repetitive head-foot movement of its incorporated platform at about 140 times per minute over a period of 45 minutes.
Dr. Adams, Bassuk and associates investigated the potential of WBPA given pre- and during experimental hemorrhage on survival rates in a large animal model in which 70% of their resting blood volume was removed over a 150 minute period. Following this procedure, the shed blood and saline solution were returned to the animal over a 120 minute period. 67% of animals treated with WBPA survived whereas only 25% of the control group who did not receive WBPA survived. Dr. Adams commented that: “This study suggests that a clinical trial of WBPA in civilian or military trauma victims may be warranted with this technology as an alternative or complementary treatment for hemorrhagic shock. The better survival with WBPA treatment probably relates to a combination of factors including the promotion of increased release of anti-inflammatory mediators and vasodilators into the circulation such as nitric oxide, prostacyclin and adrenomedullin.”
Dr. Uryash presented data in a small animal model showing that analysis of the arterial pulse waveform provided evidence of the effectiveness of nitric oxide released with WBPA. Dr. Adams commented that, “The demonstration of such effectiveness in a small animal model will allow us to progress more rapidly toward a better understanding of the mechanisms underlying WBPA in treatment of cardiac arrest and hemorrhagic shock.”
NIMS currently supports a clinical trial to demonstrate the intended use of Exer-Rest for temporary relief of musculoskeletal pain associated with osteoarthritis of the lower extremities (hips and knees) in order to meet FDA approval for its marketing in the United States. Exer-Rest is a CE0120 Class 2 device and can be marketed and sold in the common market and Canada.
Further information on the Company can be obtained at http://www.nims-inc.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company’s filings with the Securities and Exchange Commission.
http://www.nims-inc.com
Stumble it!
